Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predicting resistance to high-dose fluticasone in eosinophilic esophagitis

A study in August's issue of Gastroenterology evaluates the efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis.

News image

Dr Marc Rothenberg and colleagues from Ohio, USA evaluated the efficacy and safety of high-dose swallowed fluticasone propionate, and dose reduction in patients with eosinophilic esophagitis.

The research team analyzed esophageal transcriptomes to identify mechanisms.

The researchers conducted a randomized, multisite, double-blind, placebo-controlled trial of daily 1760 mcg fluticasone propionate in participants age 330 years with active eosinophilic esophagitis.

The team reported that 28 participants received fluticasone propionate, and 14 participants received placebo.

After 3 months, participants given fluticasone propionate who were in complete remission received 880 mcg fluticasone propionate daily.

65% of subjects given fluticasone propionate were in complete remission after 3 months
Gastroenterology

Participants in the fluticasone propionate or placebo groups who were not in complete remission continued or started, respectively, 1760 mcg fluticasone propionate daily for 3 additional months.

The team's primary end point was histologic evidence for complete remission.

Secondary end points were partial remission, symptoms, compliance, esophageal gene expression, esophageal eosinophil count, and the relationship between clinical features and fluticason propionate responsiveness.

After 3 months, the team found that 65% of subjects given fluticasone propionate and no subjects given placebo were in complete remission.

The research team observed that 12% of those given fluticasone propionate, and 8% of those given placebo were in partial remission.

In the fluticasone propionate group, 73% of subjects remained in complete remission, and 20% were in partial remission after the daily dose was reduced by 50%.

Extending fluticasone propionate therapy in fluticasone propionate-resistant participants did not induce remission.

The researchers observed that fluticasone propionate decreased heartburn severity.

Compliance, age, sex, atopic status, or anthropomorphic features were not associated with response to fluticasone propionate.

Gene expression patterns in esophageal tissues of fluticasone propionate responders were similar to those of patients without EoE.

The researchers found evidence for heterogeneous steroid signaling in subjects who did not respond to fluticasone propionate, and preliminary evidence for transcripts predictive of fluticasone propionate responsiveness.

Dr Rothenberg's team commented, "Daily administration of a high dose of fluticasone propionate induces histologic remission in 65%77% of patients with eosinophilic esophagitis after 3 months."

"A 50% dose reduction remained effective in 73%93% of patients who initially responded to fluticasone propionate."

"Nonresponders had evidence of steroid resistance."

"Histologic and molecular markers may predict resistance."

Gastroenterol 2014: 147(2): 324333.e5
29 July 2014

Go to top of page Email this page Email this page to a colleague

 24 May 2015

Advanced search
 22 May 2015 
Colonoscopy screening for colorectal cancer
 22 May 2015 
Treatment with anti-integrin antibodies in IBD
 22 May 2015 
Care of patients with GERD
 21 May 2015 
Lymphoma in IBD
 21 May 2015 
Serrated polyps and colorectal cancer
 21 May 2015 
Imaging for hepatocellular carcinoma
 20 May 2015 
Surveillance in long-segment Barrett's
 20 May 2015 
Pancreatic neuroendocrine tumors
 20 May 2015 
Refractory metastatic colorectal cancer
 19 May 2015 
Metabolic syndrome and Barrett's
 19 May 2015 
PPIs and cryptogenic liver abscess
 19 May 2015 
Anti-integrin antibodies in IBD
 18 May 2015 
ESPGHAN celiac guidelines
 18 May 2015 
HLA haplotypes and primary sclerosing cholangitis
 18 May 2015 
Safety of PPI
 15 May 2015 
Microscopic colitis risk with PPIs/NSAIDs
 15 May 2015 
Management of nonhospitalized ulcerative colitis
 15 May 2015 
Diabetes and infections in IBD with immunomodulation
 14 May 2015 
Diagnosis of spontaneous bacterial peritonitis
 14 May 2015 
Mortality in US patients with cirrhosis
 14 May 2015 
Radiation exposure during ERCP
 13 May 2015 
Predictors of IBD
 13 May 2015 
Psychological distress and liver disease mortality
 13 May 2015 
Hypnotherapy in IBS/IBD
 12 May 2015 
Bleeding in NSAID users with H.pylori
 12 May 2015 
Capsule colonoscopy detects colorectal polyps
 12 May 2015 
Anti-TNF biologics in acute severe ulcerative colitis
 11 May 2015 
Management of Barrett's esophagus
 11 May 2015 
Marker to detect recurrence of Crohn's
 11 May 2015 
Thalidomide for IBD
 08 May 2015 
Surveillance colonoscopy in colorectal cancer
 08 May 2015 
HCV treatment with compensated cirrhosis
 08 May 2015 
Medical management of Crohn's
 07 May 2015 
Surgical complications in ulcerative colitis
 07 May 2015 
Combination therapy for noncirrhostic patients
 07 May 2015 
Anxiety and new-onset dyspepsia
 06 May 2015 
PPIs and spontaneous bacterial peritonitis
 06 May 2015 
Infant feeding and celiac disease
 06 May 2015 
Preventing recurrent C. diff infection
 05 May 2015 
Fatigue in primary sclerosing cholangitis
 05 May 2015 
Annual CT scans after esophagectomy for cancer
 05 May 2015 
Prevalence of eosinophilic esophagitis
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Response to sorafenib in hepatocellular carcinoma
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Clinical outcomes after esophagectomy
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us